number of access : ?
number of downloads : ?
ID 115654
Author
Kudo, Noriko National Center of Neurology and Psychiatry
Yamamori, Hidenaga National Center of Neurology and Psychiatry|Osaka University|Japan Community Health care Organization Osaka Hospital
Ishima, Tamaki Chiba University
Nemoto, Kiyotaka University of Tsukuba
Yasuda, Yuka National Center of Neurology and Psychiatry|Osaka University|Life Grow Brilliant Mental Clinic
Fujimoto, Michiko National Center of Neurology and Psychiatry|Osaka University
Azechi, Hirotsugu National Center of Neurology and Psychiatry
Niitsu, Tomihisa Chiba University
Ikeda, Manabu Osaka University
Iyo, Masaomi Chiba University
Fukunaga, Masaki National Institute for Physiological Sciences
Watanabe, Yoshiyuki Shiga University of Medical Science
Hashimoto, Kenji Chiba University
Hashimoto, Ryota National Center of Neurology and Psychiatry|Osaka University
Keywords
cognitive performance
matrix metalloproteinase-9
schizophrenia
Wechsler Adult Intelligence Scale
Wechsler Memory Scale
Content Type
Journal Article
Description
Aim: Matrix metalloproteinase‐9 (MMP‐9) has been shown to modulate synaptic plasticity and may contribute to the pathophysiology of schizophrenia. This study investigated the peripheral levels of MMP‐9 and its association with cognitive functions in patients with schizophrenia to see the possible involvement of MMP‐9 in pathophysiology of schizophrenia, especially in cognitive decline.
Methods: We measured the plasma levels of MMP‐9 in 257 healthy controls and 249 patients with schizophrenia, including antipsychotic drug–free patients. We also explored the possible association between plasma MMP‐9 levels and cognitive performance in healthy controls and patients with schizophrenia using the Wechsler Adult Intelligence Scale, Third Edition (WAIS‐ III), the Wechsler Memory Scale‐Revised (WMS‐R), and the Rey Auditory Verbal Learning Test (AVLT).
Results: We found that the plasma levels of MMP‐9 were significantly higher in patients with schizophrenia, including antipsychotic drug–free patients, than in healthy controls. We found a significant negative association between plasma MMP‐9 levels and cognitive performance in controls and patients with schizophrenia.
Conclusion: Together, these convergent data suggest a possible biological mechanism for schizophrenia, whereby increased MMP‐9 levels are associated with cognitive impairment.
Journal Title
Neuropsychopharmacology Reports
ISSN
2574173X
Publisher
The Japanese Society of Neuropsychopharmacology|John Wiley & Sons
Volume
40
Issue
2
Start Page
150
End Page
156
Published Date
2020-02-05
Rights
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License(https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences